News

Nanobodies, megapayoff
Enlarge image

BusinessBelgium

Nanobodies, megapayoff

04.10.2012 - Belgian Ablynx secures €8.5m upfront from Merck Inc. for the development of Nanobodies against two targets, one of them yet unknown.

Camelidae antibody developer Ablynx NV (Ghent) has inked a collaboration with US pharma major Merck & Co. Inc (MSD). The companies collaborate primarily to develop and commercialise Nanobody® candidates directed towards a certain voltage-gated ion channel. Merck also acquired the option to do the same for a second, as yet unknown, target. The deal includes a €6.5m upfront payment and another €2m compensation for research funding. With successfully passed regulatory and commercial milestones in addition to secured royalties, Ablynx will be eligible to receive up to €448 million in total. While Ablynx is in charge of the discovery of the Nanobodies, Merck gains the exclusive global rights to market them and is responsible for research, development, manufacturing and commercialisation of any Nanobody® product resulting from the collaboration. 

After Ablynx showed the proof-of-principle in 2011, things are going well for the company despite the withdrawal of US pharma giant Pfizer almost a year ago. Edwin Moses, Chairman and CEO of Ablynx commented on the new deal: "We are delighted to initiate this collaboration with Merck in the area of ion channels, where to date, monoclonal antibodies have demonstrated little success. Due to the formatting flexibility of Nanobodies, we are able to combine antibody-like selectivity and multi-specificity in one molecule, making them ideal candidates for ion channel modulators." Nanobodies® are a novel class of therapeutic proteins based on single-domain, heavy-chain antibody fragments. They link conventional monoclonal antibody advantages like high specificity with the benefits of small molecule drugs like low sensitivity to temperature and pH changes. So far, Ablynx has approximately 25 programmes in the pipeline, and seven Nanobodies at clinical development stage, including partnerships with pharma and biotech companies like Boehringer Ingelheim (cancer, Alzheimer’s), former Merck Serono (osteoarthritis), Novartis, and Merck & Co.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/nanobodies-megapayoff.html

M&ASwitzerlandFrance

31.08.2015 In order to boost its active cosmetic ingredients business, the Swiss flavour and fragrance giant Givaudan has acquired Volketswil-based Induchem Holding and all its subsidiaries.

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

M&AIrelandUK

05.08.2015 Irish pharma and biotech major Shire wants to be number one in orphan diseases, and is setting out to acquire US-American Baxalta in a US$30bn deal – by any means necessary.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • TIGENIX (B)1.28 EUR25.49%
  • BIOTECH PHARMACON (N)14.35 NOK13.89%
  • BIOFRONTERA (D)2.25 EUR10.29%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)14.00 SEK-39.13%
  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • MEDIGENE (D)7.58 EUR-5.60%

TOP

  • KARO BIO (S)39.40 SEK2378.0%
  • TRANSGENE (F)5.02 EUR74.9%
  • TIGENIX (B)1.28 EUR62.0%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • THROMBOGENICS (B)2.99 EUR-40.7%
  • BIONOR PHARMA (N)1.25 NOK-39.0%

TOP

  • KARO BIO (S)39.40 SEK4704.9%
  • ADOCIA (F)86.21 EUR426.6%
  • GALAPAGOS (B)53.99 EUR331.9%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • EVOCUTIS (UK)0.19 GBP-81.9%
  • NEUROVIVE PHARMACEUTICAL AB (S)14.00 SEK-79.4%

No liability assumed, Date: 31.08.2015